PfAMA-1-FVO[25-545]
BiologicalSubcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
NCT Number: NCT00730782
The objective of this study was to evaluate the safety of a candidate malaria vaccine (PfAMA-1) at 3 doses given at monthly intervals of 2 different dosages of AMA-1 (10 μg or 50 μg ) adjuvanted either with alum hydroxide or AS02A or Montanide ISA 720 in healthy adults not previously exposed to the parasite Plasmodium falciparum.
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 1
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
Time frame: Day 0-14 after each vaccination
Time frame: 28 days after each vaccination
Time frame: until 365 days after the first immunisation
European Vaccine Initiative
Other
Assessment of the Safety and Immunogenicity of Three Formulations of the Recombinant Pichia Pastoris Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]), Blood-Stage Malaria Vaccine in Healthy Dutch Adult Volunteers : a Phase 1, Single- Blind, Randomised, Dose-Escalating, Unicentre Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05052502
Infections, Malaria
Bangkok, Thailand
View Trial DetailsNCT04093765
Infections, Malaria
Mae Sot, Changwat Tak, Thailand
View Trial DetailsNCT04147546
Infections, Malaria
Ouagadougou, Kadiogo, Burkina Faso
View Trial DetailsNCT04577066
Infections, Malaria
Leiden, Netherlands
View Trial Details